Association Between Drug Related Problems and Outcomes of Tuberculosis Patients at Citra Husada Hospital Jember
DOI:
https://doi.org/10.35451/4h3axm73Keywords:
DS-TBC, Drug Related Problem (DRP), Drug Interaction, Adverse Drug Reaction (ADR), Outcome Therapy of TBCAbstract
Background: Tuberculosis (TBC) remains a major global challenge. In Indonesia, the success rate for Drug-Sensitive Pulmonary TB (DS-TBC) treatment is still below target, often linked to Adverse Drug Reaction (ADR) and Drug Related Problem (DRP). The complexity of regimens and polypharmacy increases the risk of DRPs, which are strong predictors of treatment failure. Objective: This study aimed to identify DRPs and analyze their relationship with the clinical outcomes of DS-TBC. Method: A retrospective cohort study was conducted on 281 DS-TBC patients recorded at Citra Husada Hospital Jember from January 2020 to December 2023. Data were collected from medical records and the TBC Information System (SITB). DRPs were identified using the PCNE V9.1 classification, focusing on dose inappropriateness, drug interactions, and ADR. Outcomes were categorized as successful (cured/treatment completed) or unsuccessful. Result: Data analysis included descriptive statistics, bivariate analysis using Chi-Square, and multivariate analysis using Binary Logistic regression with a significance p < 0,05. The result of this study is that patients were predominantly male (55.16%), aged 46-65 years, with a treatment completion rate of 82.21%. DRPs were found in 84.34% of patients, dominated by drug interactions (79%) and ADRs (35.23%), although the accuracy of anti-TB drug dosage was 100%. In multivariate analysis, age ≥65 years was associated with a decreased likelihood of successful treatment (aOR 0.367), while respiratory tract medication administration was associated with an increased likelihood of successful treatment (aOR 2.477). The overall relationship between DRPs and outcome was not statistically significant. Conclusion: Sociodemographic factors (age) and clinical symptom management (respiratory therapy) play the most crucial roles in determining the treatment outcome. Effective pharmaceutical intervention is suggested to mitigate the impact of DRPs on treatment failure. More aggressive clinical management is necessary for elderly patients.
Downloads
References
[1] Ali, S., Rao, M., Sahly, A. A., Alfageeh, A., & Bakari, A. (2018). Co-Management of Active Tuberculosis and Diabetes Mellitus Under Supervised DOTS Strategy—A Saudi Perspective. Reports, 1(3), 25. https://doi.org/10.3390/reports1030025
[2] Awad, K., Jaam, M., Awaisu, A., Stewart, D., Rathore, A., Hadi, M. A., Awad, K., Jaam, M., Awaisu, A., Stewart, D., Rathore, H. A., Abdul, M., & Impact, H. (2024). Impact of pharmaceutical care interventions in improving clinical outcomes among patients with pulmonary tuberculosis : a systematic review. 3211. https://doi.org/10.1080/20523211.2024.2305770
[3] Ayeni, F. A., Ambeke, Y. P., & Aina, B. A. (2023). Drug related problems in type 2 diabetic patients with tuberculosis: a prospective study. 2(1), 1–12.
[4] Bagisheva, N. V., Mordyk, A. V., Viktorova, I. A., Trukhan, D. . ., Nesterova, K. I., Moiseeva, M. V., Batishcheva, T. L., & Aroyan, A. R. (2021). Possibilities of combined bronchodilator therapy in the complex treatment of patients with comorbid pathology : focusing on patients with newly diagnosed tuberculosis and chronic obstructive pulmonary disease. Pharmateca, 10, 93–98.
[5] Chethkwo, F., Tanih, N. F., Nsagha, D. S. (2024). Analysis of the Outcomes of Tuberculosis Treatment and Factors Associated with Successful Treatment at the Bamenda Regional Hospital: A 10‑year Retrospective Study Fabrice. International Journal of Mycobacteriology, 13(1), 65–72. https://doi.org/10.4103/ijmy.ijmy
[6] Djochie, R. D. A., Anto, B. P., & Opare-Addo, M. N. A. (2023). Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study. Journal of Pharmaceutical Policy and Practice, 16(1), 1–10. https://doi.org/10.1186/s40545-023-00577-6
[7] Drugbank. (2025). Drug Interaction Checker. https://go.drugbank.com/drug interaction checker. 25–26.
[8] Endalifer, B. L., & Ayta, Y. D. (2025). Drug-therapy-related problems and pharmacist interventions in the medical ward in northeast Ethiopia : focus on types , acceptability , and impacts. April, 1–12. https://doi.org/10.3389/fphar.2025.1558864
[9] Feldman, C., Theron, A. J., Cholo, M. C., & Anderson, R. (2024). Cigarette Smoking as a Risk Factor for Tuberculosis in Adults: Epidemiology and Aspects of Disease Pathogenesis. Pathogens, 13(2), 1–16. https://doi.org/10.3390/pathogens13020151
[10] Forget, E. J., & Menzies, D. (2006). Adverse reactions to first-time antituberculosis drugs. Expert Opinion on Drug Safety, 5(2), 231–249. https://doi.org/10.1517/14740338.5.2.231
[11] Fortuna, T. A., Rachmawati, H., Hasmono, D., & Karuniawati, H. (2022). Studi Penggunaan Obat Anti Tuberkulosis (OAT) Tahap Lanjutan pada Pasien Baru BTA Positif The Study of Continuation Phase Anti Tuberculosis Drugs (OAT) in New Patient with Smear-Positive. Pharmacon Jurnal Farmasi Indonesia, 19(1), 62–71. http://journals.ums.ac.id/index.php/pharmacon
[12] Fortuna, T. A., Rahmawati, F., & Yasin, N. M. (2021). Hubungan Drug Related Problems (DRPs) dan Outcome Pengobatan Pada Pasien Tuberkulosis Dengan Diabetes Melitus. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice), 11(2), 122. https://doi.org/10.22146/jmpf.62602
[13] Fretes, F. de, Desimina Tauho, K., & Mayopu, B. E. (2022). Analisis Program Pengendalian Tuberkulosis dengan Strategi DOTS di Puskesmas Manutapen Kupang. Jurnal Epidemiologi Kesehatan Komunitas, 7(2), 482–489.
[14] Ganga, N. P. (2022). Polypharmacy: An overview. Journal of Pharmaceutical Care, 10(4), 229–233. https://doi.org/10.18502/jpc.v10i4.11584
[15] Zhou D, Chen Z, Tian F. Deprescribing interventions for older patients: a systematic review and meta-analysis. Journal of the American Medical Directors Association. 2023 Nov 1;24(11):1718-25.
[16] Guo, J., Liu, Z., Feng, Y., Luo, S., Jiang, Q., Guo, J., Liu, Z., Feng, Y., Luo, S., & Jiang, Q. (2023). Assessment of Effective Anti-TB Regimens and Adverse Outcomes Related Risk Factors in the Elderly and Senile-Aged TB Patients Assessment of Effective Anti-TB Regimens and Adverse Outcomes Related Risk Factors in the Elderly and Senile-Aged TB Patients. 6973. https://doi.org/10.2147/IDR.S414918
[17] Kamila, D. A., Wardani, H. E., Tama, T. D., Anindya Hapsari, & Gayatri, R. W. (2023). Determinant of Successful Tuberculosis Treatment in Puskesmas Singosari in 2020-2022. Keluwih: Jurnal Kesehatan Dan Kedokteran, 5(1), 7–19. https://doi.org/10.24123/kesdok.v5i1.5972
[18] Kementerian Kesehatan Republik Indonesia. (2023). Temu Media Hari Tuberkulosis Sedunia 2023: Wujudkan Pekerja Bebas TBC untuk Indonesia. Https://Tbindonesia.or.Id/Temu-Media-Htbs-2023/, 1–8.
[19] Kementerian Kesehatan RI. (2020). Pedoman Nasional Pelayanan Kedokteran: Tatalaksana Tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia. https://doi.org/10.1088/1751-8113/44/8/085201
[20] Kementerian Kesehatan RI. (2023). Laporan Program Penanggulangan Tuberkulosis Tahun 2022. 1–147. https://tbindonesia.or.id/pustaka_tbc/laporan-tahunan-program-tbc-2021/
[21] Khan, F. U., & Khan, F. U. (2023). A randomized controlled trial to evaluate the impact of pharmacist-led clinical interventions on the health-related quality of life among TB patients. May, 1–14. https://doi.org/10.3389/fphar.2023.1171985
[22] Khotimah, K., & Sutrisna, E. (2023). IDENTIFIKASI DRUG RELATED PROBLEMS (DRPs) PENGOBATAN TUBERKULOSIS TAHAP INTENSIF PADA PASIEN GERIATRI DI RSUP SURAKARTA. Medical Sains : Jurnal Ilmiah Kefarmasian, 8(3), 945–954. https://doi.org/10.37874/ms.v8i3.750
[23] Lamria, P., Kristina, Dian, P., Teti, T., & Dina Bisara, L. (2020). Faktor-Faktor yang Mempengaruhi Kejadian Tuberkulosis pada Umur 15 Tahun ke Atas di Indonesia (Analisis Data Survei Prevalensi Tuberkulosis (SPTB) Di Indonesia(2015-2020). Buletin Penelitian Sistem Kesehatan, 23(1), 10–17.
[24] Lolong, D. B., Aryastami, N. K., Kusrini, I., Tobing, K. L., Tarigan, I., Isfandari, S., Senewe, F. P., Raflizar, Endah, N., Sitorus, N., Pangaribuan, L., Simarmata, O. S., & Ariati, Y. (2023). Nonadherence to anti-tuberculosis treatment, reasons and associated factors among pulmonary tuberculosis patients in the communities in Indonesia. PLoS ONE, 18(8 August), 1–12. https://doi.org/10.1371/journal.pone.0287628
[25] Mahartati, N. M. N., & Syarif, S. (2024). Faktor Risiko Kegagalan Pengobatan Tuberkulosis: Systematic Review. 7(4), 899–906.
[26] Main, S., Lestari, T., Triasih, R., Chan, G., Davidson, L., Majumdar, S., Santoso, D., Phung, S., Laukkala, J., Graham, S., Du Cros, P., & Ralph, A. (2019). Training for tuberculosis elimination in Indonesia: Achievements, reflections, and potential for impact. Tropical Medicine and Infectious Disease, 4(3). https://doi.org/10.3390/tropicalmed4030107
[27] Martin, S. J., & Sabina, E. P. (2019). Malnutrition and Associated Disorders in Tuberculosis and Its Therapy. Journal of Dietary Supplements, 16(5), 602–610. https://doi.org/10.1080/19390211.2018.1472165
[28] Musnelina, L., Putri, E. T., Pontoan, J., & Putri, S. N. (2024). JOPS : Journal of Pharmacy and Science Assessment of the Appropriateness of Antituberculosis Drug Utilization in Pulmonary Tuberculosis Patients Pendahuluan Metode Analisis Data Data dikumpulkan dengan teknik dokumentasi menggunakan data sekunder lembar r. 7(2), 78–84.
[29] Niazi, A. K., & Kalra, S. (2012). Diabetes and tuberculosis: A review of the role of optimal glycemic control. Journal of Diabetes and Metabolic Disorders, 11(1), 9–12. https://doi.org/10.1186/2251-6581-11-28
[30] Noveyani, A. E., & Martini, S. (2013). EVALUASI PROGRAM PENGENDALIAN TUBERKULOSIS PARU DENGAN STRATEGI DOTS DI PUSKESMAS TANAH KALIKEDINDING SURABAYA Evaluation the Pulmonary Tuberculosis Control Program with Strategy DOTS in Puskesmas Tanah Kalikedinding Surabaya. 251–262.
[31] Nurjana, M. A. (2018). Faktor Risiko Terjadinya Tuberculosis Paru Usia Produktif (15-49 Tahun) Di Indonesia Risk Factors of Pulmonary Tuberculosis on Productive Age 15-49 Years Old in Indonesia. Media Litbangkes, 25, 165–170.
[32] Pangestu, F. R., Soleha, T. U., & Oktarlina, R. Z. (2023). Hubungan Ketepatan Terapi Obat Anti Tuberkulosis terhadap Kesembuhan Pasien Tuberkulosis Paru. Medula, 13(4), 559–562.
[33] PCNE. (2020). PCNE Classification for Drug-Related Problems V9.1. PCNE Association, 1(2), 22–28. http://www.pcne.org/upload/files/15_PCNE_classification_V4-00.pdf
[34] Peng, Y., Cheng, Z., & Xie, F. (2021). Evaluation of pharmacokinetic drug-drug interactions: A review of the mechanisms, in vitro and in silico approaches. Metabolites, 11(2), 1–16. https://doi.org/10.3390/metabo11020075
[35] Perhimpunan Dokter Paru Indonesia. (2021). Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. In Perhimpunan Dokter Paru Indonesia (Vol. 001, Issue 2014).
[36] Permadi, Y. W., Akrom, Imam Riadi, & St Rahmatullah. (2025). Analisis Polifarmasi Terhadap Interaksi Obat Di Rumah Sakit Umum Kota Pekalongan. Lambda Jurnal Ilmiah Pendidikan MIPA Dan Aplikasinya, 5(1), 69–82. https://doi.org/10.58218/lambda.v5i1.1200
[37] Pooranagangadevi, N., & Padmapriyadarsini, C. (2022). Treatment of Tuberculosis and the Drug Interactions Associated With HIV-TB Co-Infection Treatment. 3(May), 1–11.
[38] Pradipta, I. S., Idrus, L. R., Probandari, A., Lestari, B. W., Diantini, A., Alffenaar, J. W. C., & Hak, E. (2021). Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis setting: a qualitative study from the patient’s perspective. BMC Public Health, 21(1), 1–12. https://doi.org/10.1186/s12889-021-12005-y
[39] Pramono, J. S., Sudding, R., & Tini, T. (2023). Relationship between Side Effects of Anti-tuberculosis Drugs (ATDs) and Adherence to Medication in Elderly Patients with Tuberculosis. Poltekita : Jurnal Ilmu Kesehatan, 17(2), 326–333. https://doi.org/10.33860/jik.v17i2.2020
[40] Putra, G. W., & Pradnyani, P. E. (2022). Determinan Keberhasilan Pengobatan Pasien Tuberkulosis di Kota Denpasar Tahun 2021 Pendahuluan. 10(2), 66–72. https://doi.org/10.47007/inohim.v10i2.429
[41] Rakhmawati, N. D., Saefurrohim, M. Z., & Warsono, W. (2023). Analysis of Factors Contributing to Treatment Success among Tuberculosis Patients: Cross-Sectional Study in Semarang, Indonesia. Media Keperawatan Indonesia, 6(1), 25. https://doi.org/10.26714/mki.6.1.2023.25-32
[42] Salsabila, M., Kusumawati, S., & Tuba, S. (2019). Identifikasi Pengobatan Tuberkulosis Pada Pasien Rawat Jalan. 7(4), 531–535.
[43] Sant-Anna, F. M., Araújo-Pereira, M., Schmaltz, C. A. S., Arriaga, M. B., Andrade, B. B., & Rolla, V. C. (2023). Impact of adverse drug reactions on the outcomes of tuberculosis treatment. PLoS ONE, 18(2 February), 1–14. https://doi.org/10.1371/journal.pone.0269765
[44] Costello J, Barras M, Foot H, Cottrell N. The impact of hospital-based post-discharge pharmacist medication review on patient clinical outcomes: a systematic review. Exploratory research in clinical and social pharmacy. 2023 Jul 13;11:100305.
[45] Shahzad, A., Farhad Anwar, M., Hussain Mian, A., Rehman, A., & M, M. (2021). Pharmacotherapy of Different Tuberculosis Patients its Analysis and Outcomes: A Retrospective Cohort Study. Journal of Biomedical Research & Environmental Sciences, 2(11), 1154–1158. https://doi.org/10.37871/jbres1363
[46] Sugihantono, Nadya, A., Nanang, Salmasfattah, Novyananda, V., & Bagas, R. A. (2023). Analisis Drug Related Problems Kategori Overdose , Underdose, Dan Drug Interaction. Jurnal Kesehatan Medika Udayana, 09(02), 159–170.
[47] Veryanti, P. R., Dewi, N. P. K., & Pertiwi, D. (2019). Potensi Interaksi Obat Anti Tuberkulosis di Instalasi Rawat Inap RSUD X Jakarta Periode 2016. Saintech Farma: Jurnal Ilmu Kefarmasian, 12(1), 23–31.
[48] WebMD LLC. (2024). Medscape Drug Interaction Checker. Medscape. https://reference.medscape.com/drug-interactionchecker
[49] World Health Organization. (2022). Global Report 2022. In Analytical Biochemistry (Vol. 11, Issue 1). http://link.springer.com/10.1007/978-3-319-59379-1%0Ahttp://dx.doi.org/10.1016/B978-0-12-420070-8.00002-7%0Ahttp://dx.doi.org/10.1016/j.ab.2015.03.024%0Ahttps://doi.org/10.1080/07352689.2018.1441103%0Ahttp://www.chile.bmw-motorrad.cl/sync/showroom/lam/es/
[50] Yeswanth Raja, B., & Ganachari, M. S. (2024). Identification and evaluation of drug related problems to first line therapy of antitubercular drugs among the pulmonary tuberculosis patients in a tertiary care hospital- A Randomised controlled study. International Journal of Pharmaceutical Sciences and Drug Research, 16(2), 142–148. https://doi.org/10.25004/ijpsdr.2024.160202
[51] Yin, J., Wang, X., Zhou, L., & Wei, X. (2018). The relationship between social support, treatment interruption and treatment outcome in patients with multidrug-resistant tuberculosis in China: a mixed-methods study. Tropical Medicine and International Health, 23(6), 668–677. https://doi.org/10.1111/tmi.13066
[52] Marbun RA. The Relationship between the Availability of Essential Medicines and Outpatient Satisfaction in the Pharmaceutical Installation. JURNAL KEPERAWATAN DAN FISIOTERAPI (JKF). 2025 Aug 12;7(2):371-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Lutvi Anggraeni, Fifteen Aprila Fajrin, Afifah Machlaurin, Irma Prasetyowati, Angga Mardro Rahardjo
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
